Vancouver-based psychedelic drugs company Clearmind Medicine has partnered with IMP Clinical Supply Services to handle the global clinical supply chain for its drug candidate, CMND-100. IMP will ensure the smooth delivery of the drug to clinical sites, adhering to industry standards.
The partnership with IMP ensures that Clearmind's clinical trial for CMND-100, aimed at treating alcohol use disorder (AUD), can proceed without delays or supply chain issues. The trial is expected to start in Q2 2023 in the US and Israel and will assess the safety, pharmacokinetics/pharmacodynamics, and efficacy of CMND-100 in reducing drinking patterns and cravings in individuals with AUD.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.